Identifying High-Risk Prostate Cancer
Every case of prostate cancer progresses differently. While some forms progress slowly, others can quickly become dangerous. To provide patients with the most appropriate treatments, it is essential to better distinguish low-risk cancers from the most aggressive forms as early as the initial stages of the disease.
Hidden clues in the blood
Researcher Andrei Drabovich and his team at the University of Alberta are developing an innovative approach to improve diagnostics of prostate cancer and better identify its aggressive forms. They study autoantibodies produced by the immune system in response to prostate-specific proteins secreted into blood during initiation and progression of prostate cancer.
The project uses cutting-edge technologies of mass spectrometry and proteomics, which allow for the highly precise analysis of the different antibody signatures present in a blood sample. By comparing the profiles of patients with low-risk cancers to those with more aggressive cancers, the team aims to identify markers capable of predicting disease progression.
This research, funded by the Cancer Research Society (CRS), aims to better distinguish between different forms of prostate diseases and to develop a more precise test to predict aggressive prostate cancers.
This grant was absolutely essential in allowing us to continue our project. We hope to develop tools that improve detection and diagnosis for patients and enable better care. Thank you to the donors for their invaluable support.
Your impact
Improving cancer detection means giving patients a better chance from the earliest stages of the disease. By identifying the most aggressive forms sooner, research enables faster decision-making, more tailored treatments, and more effective care pathways, where it matters most.
Project Title:Precision serology of prostate cancer
Alberta
2024-2026,
$130,000
Project co-funded with
